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Lack of increased urine calcium-oxalate supersaturation in long-term
kidney transplant recipients. Nephrolithiasis is uncommon after kidney
transplantation. However, calcium (Ca) supplementation, which has been
proposed as a treatment of post-transplant osteopenia, might increase
calciuria and bolster Ca stone formation. Therefore, in 24-hour urine of 82
normocalcemic long-term renal transplant recipients (RT) and in 82
healthy subjects (HS), we assessed some Ca ncphrolithiasis risk factors
and the Ca-salt saturation estimated by the ion-activity product index (AP)
and relative supersaturation (RS). In RT, calciuria was lower (mean SD,
3.20 2.25 vs. 4.61 1.71 mmol/day; P < 0.001), urinary volume higher
(2.41 0.83 vs. 1.39 0.53 liter/day; P < 0.001), oxaluria higher (419
191 vs. 311 79 smol/day; P < 0.001) and citraturia lower (1.40 1.36
vs. 3.77 1.36 mmol/day; P < 0.001) than in HS. As a result, Ca-oxalate
supersaturation was lower in RT than HS (AP, 1.07 0.69 vs. 2.07 1.13,
P < 0.001; and RS, 0.62 0.26 vs. 0.94 0.21, P < 0.001), and was similar
in subgroups of RT (N = 37) and HS (N = 37) matched for urinary
volume, demonstrating that even without any larger urinary volume,
Ca-oxalate saturation was not higher in RT than HS, and suggesting that
opposite changes in Ca and oxalate in RT likely canceled their effects on
lithogenic risk. In RT which had similar urinary pH and phosphate (P)
than HS, Ca-P supersaturation was lower than in HS for brushite (AP,
3.25 6.67vs. 6.01 4.85, P < 0.001; RS, —0.33 0.76 vs. 0.48 0.53,
P < 0.001) and octacalcium phosphate (RS, —0.95 0.72vs. 0.21 0.85,P < 0.001), and similar for apatite. Finally, fasting calciuria and calciuric
response to a single oral Ca load were similar in RT (N = 19) and HS(N = 8). Together, these results argue strongly against a higher risk of Ca
stone formation in RT than HS, even in case of Ca supplementation.
Bone loss commonly occurs after kidney transplantation and
aggravates the pre-existing renal osteodystrophy, leading to os-
teopenia, which is considered a major complication in graft
recipients [11. Among the drugs commonly used to oppose
rejection of the graft, steroids are known to induce osteoporosis
and cyclosporine has been hypothetized to contribute to hone loss
[21. In addition, persistent hyperparathyroidism and renal phos-
phate wasting are frequently observed in renal transplant recipi-
ents (RT), in whom they likely contribute to post-tranpiant bone
disease [3—I• A single calcium (Ca) load acutely relieved the two
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latter metabolic abnormalities [6], which were also corrected
long-term by a continuous treatment with Ca and vitamin D
analogues [7]. Therefore, it was suggested that a Ca—vitamin D
supplementation may be beneficial for bone in RT [7, 8]. Unfor-
tunately, the latter issue has not been tested previously and
further studies following long-term treatment are needed. How-
ever, since they increase urinary excretion of Ca, these therapeu-
tics might theoretically favor Ca stone formation in the kidney [9].
Spontaneous occurrence of urinary calculi after kidney transplan-
tation have been rarely reported [10], but the risk of Ca stone
formation linked to Ca supplementation has not hen studied in
RT. Futhermore, we are not aware of any extensive evaluation of
urinary lithogenic risk factors in RT. Although with proper
medical and surgical management renal calculi did not seem to
impair survival and function of the graft [10, 111, the occurrence
of a stone in the graft cannot be taken as a trifling complication in
kidney recipients.
Therefore, in an attempt to assess the main biological variables
which delineate the condition of Ca lithogenesis, we studied
24-hour urinary Ca excretion in 82 renal transplant recipients
(RT) and in a control group of 82 healthy subjects (HS). In some
subjects of these two groups, calciuria was assessed both in the
fasting state and after an acute oral Ca load. We also studied
other sizeable factors of Ca stone formation in the 24-hour urine
sample: oxalate, phosphate (P), citrate, magnesium (Mg), uric
acid, pH and urinary volume. Lastly, in order to evaluate the
actual risk of Ca stone occurrence, we estimated the 24-hour
urinary saturation level for Ca-oxalate and for the main crystalline
forms of Ca-P salts encountered in calculi: apatite, brushite and
octacalcium phosphate (octaCa-P).
Methods
Subjects
We studied 82 RT grafted for at least six months and 82 HS
matched for age, sex and body mass index (BMI). The main
characteristics of the two groups of subjects are listed in Table 1.
We selected RT with a good renal function (creatinine clearance
equal to or higher than I mI/second/1.73 m2) and no hypercalce-
mia (calcemia lower than 2.6 mmol!liter) nor vitamin deficiency
(serum 250HD higher than 19 nmol/liter using the 125J RIA kit;
INCSTAR, Stillwater, MN, USA). All these recipients were
treated with cyclosporine, azathioprinc, and low doses steroid
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Table 1. Characteristics and results (mean SD) of renal transplant
recipients (RT, N = 82), and of healthy subjects (HS, N = 82)
Normal
valuesVariables
Subject number
(men/women)
Age years
Body weight kg
Height m
BMI kg/rn2
Dietary Ca intakc
mrnoi/day
Serum creatinine
pinol/liter
Creatinine clearance
rn//second/i. 73 m2
24-hour urinary
creatinine rnrnoi/day
Serum Ca rnrnol/liter
Serum P mrnol/liter
Serum Mg mrnol/liter
Serum uric acid
pinol//iter
Serum Na mmoi/iiter
Serum K rnrnol/liter
Serum Cl rnrnol/liter
Serum total CO2
rnrnol//iter
24-hour urinary
volume liter/day
24-hour urinary pH
24-hour urinary Ca
rnmol/day
24-hour urinary oxalate
pmol/day
24-hour urinary Mg
mrnol/day
24-hour urinary citrate
mrnol/day
24-hour urinary P
mmoi/day
24-hour urinary
uric acid nrnoi/day
24-hour urinary Na
mmol/day
24-hour urinary K
mmoi/day
24-hour urinary Cl
mmol/day
p
Ca-oxalate AP 1.07 0.69 0.001 2.07 1.13
Apatite AP 16.0 36.3 NS 16.2 57.6
Brushite AP 3.25 6.67 0.001 6.01 4.85
Ca-oxalate RSh 0.62 0.26 0.001 0.94 0.21
Octacalcium —0.95 0.72 0.001 0.21 0.85
phosphate RS'
Brushite RS" —0.33 0.76 0.001 0.48 0.53
NS is nonsignfiicant.
a Twenty-four-hour urinary ion-activity product index (AP) for Ca-
oxalate and Ca-P (apatite and brushite), according to Tiselius [14, 151
Twenty-four-hour urinary relative saturation (RS) for Ca-oxalate and
Ca-P (oetacalcium phosphate and hrushitc), according to Marshall and
Robertson [16]
cause of original end-stage renal disease, and none had history of
kidney stones or urinary infection at the time of the study. No RT
or HS had any pathology or treatment known to influence oxalate,
citrate, calcium-phosphorus (Ca-P) or bone metabolisms.
All the subjects were ambulatory and were maintained on their
customary diet, solid and fluid. Thus, HS were in free diet, and RT
were following the nutritional advices given after transplantation
by the dietician. Especially, RT are instructed to track a protein
intake close to ito 1.2 g/kg/day and to avoid too large an intake
of sodium chloride. They had no restriction of water or Ca intake,
but were conversely instructed to drink ad libitum (at least 1.5
liter/day) and to have a nutritional Ca intake considered as
optimal (about 1 g/day). RT and HS were not taking any
medicinal Ca supplementation at the time of the study, and their
actual dietary Ca intake was assessed by a dietician using a food
frequency questionnaire [12]. Furthermore, in order to avoid
circumstancial excess in oxalate intake, the subjects were advised
to avoid some oxalate rich foods, such as chocolate, spinach,
endive, rhubarb, beet green, and large amounts of tea or cocoa.
The ethics committee of our university hospitals approved the
project of the study. All the subjects volunteered for inclusion
after complete explanation of the aims and design of the study.
Design of the study
Each subject had a 24-hour baseline evaluation that consisted
of a 24-hour urine collection without preservative and a blood
sample taken at 0800 hours after an overnight fast. From the
samples, serum measurements of Ca, P, uric acid, creatinine,
albumin, sodium (Na), potassium (K), chloride (Cl), total carbon
dioxide (total C02) were performed, and urine pH, Ca, P, Mg,
citrate, oxalate, uric acid, creatinine, Na, K, Cl and volume were
measured. In 24-hour urine sample we also estimated Ca-oxalate
and Ca-P activity products, which delineate the level of urine
saturation. Since the daily survey of individual results rapidly
revealed that RT had often a higher 24-hour urinary volume than
HS, we compared subgroups of subjects with similar urine output,
to assess the role of solutes independently of the solvent volume
in Ca salts saturation.
In addition, we also studied both fasting calciuria and calciuric
response to an oral Ca load in 19 RT and 8 HS randomly chosen
among the entire groups. Therefore, after collection of a two-hour
fasting urine sample, the recumbent subjects ingested 1 g Ca at
0800 hours (Ca gluconolactate and carbonate, Calcium-Sandoz
"Forte"®; Sandoz, Rueil-Malmaison, France) and urine was then
collected hourly during four hours for measurements of Ca and
creatininc.
Biochemical analyses
Ca, P, Mg, uric acid, creatininc and albumin were measured by
a colorimetric method, with a multi-test analyzer (ERIS 6170;
Eppendorf, Hamburg, Germany). Quantitative determination of
Na, K, Cl and total CO2 were made with ion-selective electrodes
(E4A Electrolyte Analyzer; Beckman Instruments, Brea, CA,
USA), and urinary pH was measured using a pH-meter (CG 840;
Schott, Hofhcim, Germany). Urinary citrate was determined with
an enzymatic UV-method using citrate lyase (Boehringer, Mann-
heim, Germany). Interassay variations were 6.6%. Urinary oxalate
was precipitated with calcium sulfate in water-alcoholic environ-
ment and subsequently enzymatically measured using oxalate
RT
82 (47/35)
44.3 12.8
67.1 14.9
1.67 0.09
23.8 3.9
26.4 9.2
111.0 19.5
1.26 0.24
11.9 2.8
NS
NS
NS
NS
NS
0.001
0.001
0.01
HS
82 (47/35)
44.2 14.1
69.1 12.3
1.69 0.10
24.1 3.5
24.9 9.8
81.9 11.5
1.81 0.29
13.3 3.2
2.33 0.06
1.07 0.16
0.82 0.09
275 54
2.35 0.10 NS
0.96 0.17 0.001
0.75 0.09 0.001
361 82 0.001
NS 138.7 2.7
NS 4.34 0.27
NS 103.4 1.8
0.001 26.2 1.8
60—120
1.8—2.2
8.8—17.6
2.20—2.60
0.90—1.30
0.74—0.92
145— 415
135—145
3.8—5.0
99 —108
22—30
2.5—7.0
150—440
1.7—5.9
1.6—6.2
12—3 7
1.50—475
100—200
30 —120
139.4 3.6
4.27 0.36
104.1 3.6
21.5 1.8
2.41 0.83
6.1 0.9
3.20 2.25
419 191
3.69 1.09
1.40± 1.36
25.2 9.4
2.77 0.91
138 49
69 21
0.001
NS
0.001
0.00 1
NS
0.001
NS
0.001
NS
NS
1.39 0.53
6.2 0.7
4.61 1.71
311 79
3.67 1.18
3.77 1.36
26.7 7.0
3.25 0.82
134 49
66 18
138±50 NS 133 47 100—200
(prednisone or prednisolone, 5 to 10 mg/day). No patient had
previously undergone parathyroid surgery nor received biphos-
phonate therapy, none had primary or acquired hyperoxaluria as
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Calculations and statistical methods
3.8 X Ca°7' x oxalate1°
Ca-oxalte AP =
Mg°'4 x citrate°'0 x volume'2
2.7 X i03 X Ca1'°7 X P°7° >< (p — 45)6.8
citrate°2° x volumel:3l
6.4 X 10 X Ca'°7 >< p082 x p1:168
citrate0 X volume'53
Results Discussion
oxidase (Medela-Biorea, Brussels, Belgium). Interassay variation
was 7.0%.
Serum total Ca was corrected for albumin concentration [13]
and creatinine clearance was calculated for estimation of glomer-
ular filtration rate (GFR).
The calciuric response to oral Ca load was calculated as the
difference between the average molar hourly urinary output for
the four hours following the Ca load, and the average molar
hourly urinary output during the fasting period.
The ionic activity of Ca salts was estimated by two indirect
methods in 24-hour urine collection. First, we calculated the
ion-activity product index (AP) according to the following rela-
tionships from Tiselius [14, 15]:
1.71 mmol/day; P < 0.001), oxaluria higher (419 191 vs. 311
79 pmolIday; P < 0.001), uricuria lower (2.77 0.91 vs. 3.25
0.82; P < 0.001), and citraturia lower (1.40 1.36 vs. 3.77 1.36
mmol/day; P < 0.001) than in HS (Table 1). Urinary pH, Mg and
P were not different in the two groups. There was no relationship
between daily urinary oxalate and creatinine excretions among
RT, HS or both groups together. Ca-oxalate and brushite satura-
tion assessed by AP as well as by RS, were markedly lower in RT
than HS (P < 0.001). Also, octaCa-P RS was lower in RT than HS
(P < 0.001), whereas apatite AP was similar in the two groups of
subjects. Moreover, both brushite and octaCa-P RS values were
negative in RT and positive in HS, indicating that in graft
recipients, urine was undersaturated with respect to these salts,
while it was supersaturated in healthy subjects. Lastly, there was a
strong correlation between the saturation level with Ca salts
estimated by Tiselius activity product index (AP) and by Marshall
and Robertson's relative saturation (RS), in both groups. For
Ca-oxalate, the relationship was RS 0.70 + 0.39 log AP (r =
0.97; P < 0.001), and for brushite RS = — 0.38 + 0.53 log AP (r =
0.92; P < 0.001). Thus, these two methods led to very similar
results. There was a negative linear relationship between Ca salts
supersaturation and daily urinary volume, consistent for Ca-
oxalate (RS = 1.27—0.26 urinary volume; r = 0.77; P < 0.001; Fig.
1) and somewhat looser for brushite (RS = 1.04—0.51 urinary
volume; r = 0.58; P < 0.001).
In the subgroups of 37 RT and 37 HS with matched urinary
volume, oxaluria was higher and calciuria, citraturia and uricuria
lower in RT than HS (P < 0.001), while magnesiuria was not
different between RT and HS (Table 2). Apatite AP was similar in
RT and HS, whereas brushite and octaCa-P RS values were lower
in RT than HS (P < 0.001). These results of 24-hour urinary risk
factors and saturation levels superimposed those obtained in the
whole groups. Conversely, both Ca-oxalate AP and RS, and
brushite AP were similar in the two subgroups with matched
urinary volume, while in the whole groups, they were lower in RT
than HS.
Fasting calciuria and calciuric response to oral Ca load
Neither urinary excretion of Ca in the fasting state, nor its
increase during the four hours following Ca ingestion were
different between RT and HS (Table 3).
Two main reasons convinced us to undertake this study. First,
there are scarce data about factors favoring stone formation after
kidney transplantation, although the occurrence of calculi in the
graft could be a serious complication in recipients. Second,
long-term Ca supplementation, suggested as a therapy for post-
transplant bone disease, might theoretically increase the risk of Ca
stone formation.
The main findings of our comparison of RT with HS were that,
despite a moderatly higher oxaluria and a markedly lower citra-
tuna in RT, their 24-hour urinary Ca-oxalate supersaturation was
markedly lower than in HS, and they also had a lower calciuria
and a larger urinary volume. In addition, urinary pH and phos-
phate were similar in RT and in HS, leading to a lower 24-hour
urinary Ca-P saturation in RT than HS for brushite and octaCa-P,
whereas saturation with apatite was similar in the two groups.
Furthermore, fasting calciuria and calciuric response to an acute
oral Ca load were similar in RT and HS.
Apatite AP = ___________________________________
Brushite AP =
Second, we used the nomograms from Marshall and Robertson
[161, which allow the estimatation of saturation in Ca-oxalate,
brushite and octaCa-P from urinary concentrations of Ca, oxalate,
and P and urinary pH. The result was defined on a log relative
saturation (RS) scale. On this scale, an urine at the solubility
product or at the formation product has RS value of 0 and 1,
respectively. Therefore, a negative RS value indicates that urine is
undersaturated with the constituent concerned. A value between
0 and 1 indicates the metastable region of urine supersaturation.
Finally, a RS greater than 1 indicates that spontaneous crystal-
lisation is likely to occur.
Values are given as mean SD. Unpaired Student's t-test were
used to compare data of the two groups of subjects and significant
changes overtime after oral Ca load were assessed by two-way
ANOVA with repeated measures. Linear regression and correla-
tion analysis was used to test correlation between variables.
Sex ratio, age, body wt, height, BMI and daily Ca intake were
similar in RT and in HS (Table 1), In RT, post-tranplantation
time ranged from 6 to 73 months. Although we studied only
recipients with good renal function, our RT had higher serum
creatinine and lower creatinine clearance than the control HS
(P < 0.001). Indeed, in RT serum creatinine was at the upper limit
of the usual normal range, and creatininc clearance was only
moderatly decreased. The daily urinary excretion of creatinine
was slightly lower in RT than HS. Serum Ca, Na, K, Cl and urinary
Na, K and Cl, were similar in the two groups. tn RT, serum total
C02, Mg and P were moderately lower (P <0.001) and serum uric
acid was higher than in HS (P < 0.001).
Urinary Ca stone risk factors and Ca salts supersaturation
In RT, the urinary volume was higher (2.41 0.83 vs. 1.39
0.53 liter/day; P < 0.001), calciuria lower (3.20 2.25 vs. 4.61 ±
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Fig. 1. Relationship between Ca salt relative supersaturation (RS) according
to Marshall and Robertson [16/, and daily urina,y volume in 82 renal
transplant recipients (•) and 82 healthy control subjects (). A. For
Ca-oxalate the relationship was: RS = 1.27—0.26 urinary volume; r = 0.77;
P < 0.001. B. For brushite the relationship was: RS 1.04—0.51 urinary
volume; r = 0.58; P < 0,001.
Risk of spontaneous Ca-oxalate stone formation in RT
The primary determinants of Ca-oxalate saturation are concen-
trations in both Ca and oxalate [171. When hypercalciuria was
observed in kidney recipients, it was mainly a consequence of
hypercalcemia, commonly ascribed to severe hyperparathyroidism
[18, 19]. In normocalcemic long-term recipients, 24-hour calciuria
was found within normal range [20—221 or similar to values of
healthy control subjects [23, 24]. In our RT, daily Ca excretion
also remained within normal range, but at a lower value than in
Table 2. Risk factors of Ca stone formation and Ca salts
supersaturation in 24-hour urinary of renal transplant recipients (RT, N
= 37) and healthy subjects (HS, N = 37) matched for urinary volume
(mean so)
Normal
Variables RT P HS values
Subject number 37 (20/17) 37 (20/17)
(men/women)
Age years 40.8 14.0 NS 46.2 11.6
BMI kg/rn2 23.8 3.7 NS 23.6 3.0
24-hour urinary volume 1.80 0.43 NS 1.81 0.43
liter/day
24-hour urinary pH 6.24 0.85 NS 6.35 0.55
24-hour urinary Ca 2.93 2.13 0.001 4.51 1.34 2.5—7.0
mmol/day
24-hour urinary oxalate 405 158 0.001 322 79 150—440
pmol/day
24-hour urinary Mg 3.69 0.73 NS 3.67 0.79 1.7—5.9
mrnol/day
24-hour urinary citrate 1.37 1.16 0.001 4.10 1.40 1.6—6.2
mrnol/day
24-hour urinary P 25.1 10.3 NS 25.9 6.7 12—37
mmol/day
24-hour urinary 2.63 0.85 0.001 3.24 0.73 1.50—4.75
uric acid
nrnol/day
Ca-oxalate AP 1.33 0.77 NS 1.31 0.63
Apatite AP 10.9 21.3 NS 12.5 29.3
Brushite AP 3.38 3.10 NS 3.83 3.40
Ca-oxalate RSb 0.75 0.20 NS 0.79 0.17
Octacalcium —0.55 1.05 0.001 0.07 0.72
phosphate RSh
Brushite RSb —0.05 0.61 0.001 0.33 0.48
NS is nonsignificant.
"Twenty-four-hour urinary ion-activity product index (AP) for Ca-
oxalate and Ca-P (apatite and brushite), according to Tiselius [14, 15]
b Twenty-four-hour urinary relative saturation (RS) for Ca-oxalate and
Ca-P (octacalcium phosphate and brushite), according to Marshall and
Robertson [16]
Table 3. Urinary Ca excretion (mean Sn) at fasting state and after
an oral Ca load in renal transplant recipients (RT, N = 19) and in
healthy subjects (HS, N = 8).
Expression
Fasting state Post-Ca load period"
RT HS P RT HS P
jsmol Ca/hr 142 78 126 48 NS
mol Ca/hr 135 96 165 99 NS
NS is nonsignificant.
° Increase () from baseline in 4 hr-urinary excretion expressed as
hourly mol of Ca
}-IS. Several mechanisms might account for this difference. First, a
Ca deficiency or a defect in Ca absorption was unlikely in RT,
since they had a similar dietary Ca intake and fasting calciuria to
HS, and also had the same increase in Ca excretion following a
standardized oral Ca load. Second, urinary Ca excretion parallels
increases in dietary NaCl intake [25], and while an excessive
dietary salt intake has been reported in some RT [26], this was
unlikely in our recipients, who had similar daily Na, Cl and K
excretion than our HS. Third, reduction in Ca excretion more
likely resulted from some mild hyperparathyroidism commonly
observed in kidney recipients [3, 6]. Fourth, some hypocalciuria
0
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could occur in some RT as a result of a decrease in fractional
excretion of Ca due to the slight degree of renal insufficiency [27,
28].
Urinary oxalate strongly react with Ca to form Ca-oxalate
monohydrate (whewelite) or dihydrate (weddelite) [29]. High
oxaluria has been observed during 24 hours following kidney
transplantation, resuming normal levels by 72 hours [30], but we
are not abreast of any data about oxaluria in long-term recipients.
In our RT, we found a high oxaluria, without any blatant
explanation. First, primary or acquired hyperoxaluria were exclu-
sion criteria in this study. Second, a low Ca diet increases oxalate
excretion [31], but Ca intake was not different in RT and HS.
Third, nonenzymatic conversion of ascorbate to oxalate due to an
increase of urine pH during collection was also unlikely, since
urinary pH was similar in RT and HS. Fourth, urinary oxalate has
been said to depend on urinary creatinine excretion [31]. How-
ever, in our RT daily creatinine excretion was lower than in HS
and did not correlate with urinary oxalate.
Urinary volume also is a primary determinant of urinary
Ca-oxalate saturation [29], and a high urinary output clearly
decreases the clinical incidence of kidney stone [32]. Daily urinary
flow was often markedly higher in RT than HS, and the high
urinary volume in our recipients would thus strongly decrease
urine saturation with Ca salts. Such a high urinary volume could
result either from a tubular disorder of graft or from a primary
high fluid intake. Our RT had no evidence of disturbance of
extracellular volume homeostasis, and an overinterpretation of
the instruction to drink ad libitum might result in primary
polydipsia in these patients. However, we did not search whether
RT were able to maximally concentrate urine, and other studies
are needed to compare maximum urine osmolality in RT and HS
after thirsting or thirsting and the administration of antidiuretic
hormone.
We also studied citrate and Mg, which are both inhibitors of
Ca-oxalate stone formation [33], and uric acid, which conversely
promotes the crystallization of Ca-oxalate [17]. In RT, citraturia
was markedly lower than in HS, whereas Mg excretion was similar
in the two groups of subjects and uricuria was lower in RT than
HS.
In summary, on one hand our RT had higher oxaluria and lower
citraturia than the control FIS, which might favor Ca-oxalate stone
formation, but on the other hand, the graft recipients also had
lower calciuria, lower uricuria and and larger urine volume than
the healthy controls.
Thus, the final question is: to which extent might the combina-
tion of these factors change the probability of Ca-oxalate stone
formation in recipients? The Ca stone risk factors mainly influ-
ence the saturation of urine with Ca salts, while supersaturation
with Ca stone forming salts is a critical requirement for stone
formation [29]. Therefore, we assessed the Ca salts ionic activity
by AP and RS, which properly determine the supersaturation
state of urine.
The finding of a low Ca-oxalate supersaturation (Table 1)
strongly argues for lower chances of occurrence of Ca-oxalate
stone in RT than HS. The larger daily urine volume in RT was
mainly responsible for this lower saturation, as demonstrated by
the close relationship between Ca-oxalate RS and urinary volume
(Fig. 1). Further, Ca-oxalate supersaturation was identical in RT
and HS with the same daily urinary volume (Table 2), demon-
strating that even without any larger urinary volume, Ca-oxalate
saturation was not higher in RT than HS. The opposite changes,
with similar magnitude, we observed in the excretion of Ca and
oxalate in our RT apparently canceled any actual effect on urinary
Ca-oxalate supersaturation. Whereas the relative weights of Ca
and oxalate in the genesis of Ca-oxalate calculi remain debated
[34—37], our results argue for equivalent roles of Ca and oxalate
in Ca-oxalate saturation and on stone formation [291.
Risk of spontaneous Ca-P stone formation in RT
Whereas Ca-oxalate saturation is almost independent of pH
changes [291, high urinary pH is a pivotal risk factor for Ca-P
precipitation [291, while calciuria, phosphaturia, citraturia or
urinary volume play only circumstancial roles [15]. In our study
RT and HS had similar urinary pH and phosphaturia. Conversely,
citraturia was markedly lowered in RT.
It is unlikely that low citraturia in our patients resulted from
urinary tract infection or citrate malabsorbtion [35, 38], since we
studied subjects who had no evidence of urinary infection and
were without conspicuous bowel disease. Systemic acidosis, which
markedly decreases citrate clearance [39, 40], was the most
probable cause of low citraturia among RT, in whose lowered
serum total CO2 (averaging 21.5 mmol/liter) reflected a slight
degree of metabolic acidosis. This latter finding, unaccompanied
by a lower urinary pH than in HS, is reasonable evidence for renal
tubular acidosis (RTA) in RT. Such RTA could result from
proximal wasting of bicarbonate due to the common persistent
hyperparathyroidism in these patients [3], or from distal RTA in
some kidney recipients [41, 42]. However, only an incomplete
form of distal RTA was possible in our RT: (1) serum total CO2
remained very close to the lower limit of normal range; (2) neither
urine pH nor serum K were notably altered; and (3) Ca excretion
was lowered in our RT, whereas it is usually increased in distal
RTA. Finally, although in some patients a cyclosporine-induced
RTA has been suspected to favor stone formation [43, 44], this
condition was in fact rarely observed in RT [10, 11].
As a result of all the differences in Ca-P stone risk factors
between RT and HS, daily urinary saturation was similar for
apatite in RT and HS, and markedly lower in RT for brushite and
octaCa-P (Table 1). Accordingly, urine was undersaturated with
brushite and octaCa-P in RT, and supersaturated in HS. Although
the high urinary volume among RT contributes at last in part to
these findings, the relationship between urine volume and Ca-P
saturation remained moderately tight.
In the RT and HS matched for urinary volume (Table 2), the
apatite AP was similar in RT and HS, and brushite and ocataCa-P
RS remained lower in RT than HS, as in the whole group of
subjects. Only the brushite AP increased in RT to reach similar
values than in HS. Thus, these results do not support any higher
risk in grafted subjects than in HS to develop P-Ca stone disease.
Clinical evidence also argues in favor of a minute risk of
spontaneous Ca-oxalate or Ca-P nephrolithiasis in such recipients.
Indeed, urinary stone is uncommon in RT [10, Ii, 44, 45], and the
main factors contributing to stone formation were either urinary
tract infection or hypercalcemia-induced hypercalciuria, two con-
ditions which were discarded in our study, or surgical complica-
tions [3, 10, 11, 44, 45].
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Nephrolithiasis from Ca supplementation after kidney
transplantation
We undertook this study mainly to evaluate if Ca supplemen-
tation in RT might cause urinary Ca stone formation. A review of
results gathered in post-menopausal women without any kidney
graft concluded that an increased risk for urinary stone formation
is unlikely in most patients [9].
In RT, an excessive calciuric response to Ca ingestion, which
might contribute to an increased lithogenic risk, was unlikely since
they had a similar rise in calciuria following an oral Ca load than
HS, as in another study [6].
On the other hand, the idea itself that a higher dietary Ca
intake increases the risk of kidney stones had to be considered,
and is still relevant today. A recent extensive study provided no
evidence for this risk, and actually suggested the opposite trend
[32]. To explain this finding a reduced oxaluria has been hypothe-
tized to result either from a decreased oxalate absorption due to
high Ca intake, or from some unknown mechanism.
In conclusion, we assessed both the 24-hour urinary Ca salts
supersaturation and Ca stone risk factors to delineate the proba-
bility of spontaneous kidney stone occurrence in normocalcemic
long-term kidney recipients. Therefore, and although the forma-
tion of urinary calculi is unlikely explained solely by urinary
chemistry [351, our results strongly suggest that there was no
higher risk of spontaneous Ca-oxalate or Ca-P nephrolithiasis in
RT than HS.
In addition, we found that RT have a lower 24-hour calciuria,
the same fasting Ca excretion and the same calciuric response to
an acute oral Ca load than HS. Therefore, Ca supplementation
seems unlikely to create a greater risk of Ca-stone formation in
RT than HS. Furthermore, since Ca supplementation reduces
urinary excretion of oxalate, such a treatment might lower the
oxaluria which we found higher in RT than HS. On the other
hand, since citraturia was also lowered in RT, supplementation
with a citrate such as Ca salt [46] would seem appropriate in these
patients.
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